Equities
Health CarePharmaceuticals and Biotechnology
  • Price (JPY)6,837.00
  • Today's Change-22.00 / -0.32%
  • Shares traded2.83m
  • 1 Year change+7.60%
  • Beta0.9215
Data delayed at least 15 minutes, as of Jul 11 2025 07:30 BST.
More ▼
Find More Stocks
Find More Stocks
Use our equities screener to discover other potential opportunities.
 
Equities ScreenerGo to the Equities Screener

Profile data is unavailable for this security.

About the company

Chugai Pharmaceutical Co Ltd is a Japan-based company mainly engaged in the research, development, manufacture, sale, import and export of pharmaceutical products. The pharmaceutical products and medical devices for patients include ACTEMRA, Avastin, ALAGLIO, Aresensa, Kadosaira, Gazaiba, Seruseputo, Zeruborafu, Zeroda, Taruseba, Tecentoriku, Pajeta and other products. The products are mainly applied to the treatment of cancer, kidney diseases, kidney transplantation, bone and joint diseases such as rheumatoid arthritis, osteoporosis, knee osteoarthritis and locomotive syndrome, influenza, hemophilia and other diseases. The Company is also engaged in the provision of management services, transportation and storage services, as well as drug information literature research services. The Company operates within the domestic market and to overseas markets, including Switzerland, United Kingdom, Germany, France, China, Singapore, Korea and the United States.

  • Revenue in JPY (TTM)1.22tn
  • Net income in JPY410.15bn
  • Incorporated1943
  • Employees7.78k
  • Location
    Chugai Pharmaceutical Co Ltd15F, Nihonbashi Mitsui Tower2-1-1, Nihonbashi-Muro-machiCHUO-KU 103-8324JapanJPN
  • Phone+81 332816611
  • Fax+81 332812828
  • Websitehttps://www.chugai-pharm.co.jp/
More ▼

Peer analysis

Key Information
CompanyRevenue (TTM)Net income (TTM)Market capEmployeesPrice/earnings (TTM)Price/book value (MRQ)Price/cash flow (TTM)Price/sales (TTM)EPS (excl. extraordinary items, TTM)EPS (incl. extraordinary items, TTM)Revenue per share (TTM)Book value per share (MRQ)Asset turnover (TTM)Inventory turnover (TTM)Receivables turnover (TTM)Revenues per employee (TTM)Return on avg assets (TTM)Return on avg assets (5 yr avg)Return on investment (TTM)Return on investment (5 yr avg)Gross margin (TTM)Gross margin
(5 yr avg)
Net profit margin (TTM)Net Profit margin
(5 yr avg)
Quick ratio (MRQ)Interest coverage (TTM)Total debt to capital (MRQ)Payout ratio
(5 yr avg)
Revenue
(YOY change %)
Revenue
(5 yr growth rate)
Net income
(YOY change %)
Net income
(5 yr growth rate)
Capital expenditure
(5 yr growth rate)
Dividend
(5 yr growth rate)
Sun Pharmaceutical Industries Ltd903.10bn187.72bn6.89tn43.00k36.705.5529.597.6345.5545.55219.13300.990.59211.074.3312,227,540.0012.369.0915.8312.3879.5673.3820.8816.072.33272.980.031639.348.429.8714.1223.766.6631.95
Takeda Pharmaceutical Co Ltd4.58tn107.93bn6.97tn47.46k65.510.99348.011.5266.8366.832,880.434,407.010.31211.307.2596,545,170.000.73671.710.88152.0465.5167.662.365.990.52022.520.3943123.757.456.84-25.0819.539.821.72
Jiangsu Hengrui Pharmaceuticals Co Ltd600.32bn140.69bn7.46tn20.24k52.697.72--12.431.081.084.617.370.5981.816.051,442,469.0014.0212.6715.3114.0085.5085.6423.4520.069.98--0.002323.8422.633.7447.283.5328.534.60
Merck KGaA3.67tn485.45bn8.45tn62.60k17.391.6410.322.306.486.4849.0868.590.43121.884.89340,745.305.716.047.127.7059.2161.1513.2413.800.831332.430.22529.110.77655.55-1.6616.5416.4211.10
Regeneron Pharmaceuticals Inc2.08tn663.26bn9.04tn15.11k14.452.0912.274.3539.3039.30123.45271.600.39170.63472.61932,457.3012.5118.5213.8921.1386.6987.2231.9437.924.03--0.0843--8.2712.5511.6115.8415.46--
Zoetis Inc1.37tn371.19bn10.17tn13.80k27.8314.8522.867.435.575.5720.5410.440.65291.077.00672,898.6017.7715.2521.8318.3170.9870.1827.2226.321.0421.140.585628.938.338.146.0610.637.3221.37
CSL Ltd2.24tn404.66bn11.32tn30.40k28.064.1420.045.058.598.5947.6058.190.40211.254.30760,618.207.529.469.3511.7051.8053.8418.7120.110.8519.230.36846.7711.1911.6320.426.61-0.42077.26
GSK plc6.27tn627.51bn11.45tn68.63k18.474.128.371.830.76250.76257.653.420.52891.514.54459,412.206.116.269.149.8672.0170.7511.5515.560.580115.020.574580.463.46-1.45-47.75-11.136.63-9.41
Chugai Pharmaceutical Co Ltd1.22tn410.15bn11.48tn7.78k27.435.90--9.39249.23249.23742.641,158.970.60541.394.57157,125,400.0020.3219.5522.8523.9571.0165.5133.5630.126.16--0.0039.665.3311.2719.0019.71-2.1416.00
Bristol-Myers Squibb Co7.02tn798.84bn14.06tn34.10k17.595.487.062.002.662.6623.448.540.49764.275.121,396,950.005.680.65367.690.817574.6976.6311.411.521.177.390.7402678.247.3213.06-211.50--8.347.91
Data as of Jul 11 2025. Currency figures normalised to Chugai Pharmaceutical Co Ltd's reporting currency: Japanese Yen JPY

Institutional shareholders

10.90%Per cent of shares held by top holders
HolderShares% Held
Nomura Asset Management Co., Ltd.as of 03 Jul 202549.67m2.96%
Nikko Asset Management Co., Ltd.as of 04 Jul 202524.31m1.45%
The Vanguard Group, Inc.as of 02 Jul 202523.85m1.42%
Daiwa Asset Management Co. Ltd.as of 30 May 202522.68m1.35%
BlackRock Fund Advisorsas of 03 Jul 202515.17m0.90%
Mitsubishi UFJ Asset Management Co., Ltd.as of 03 Jul 202512.75m0.76%
Norges Bank Investment Managementas of 31 Dec 20249.04m0.54%
Harding Loevner LPas of 31 May 20258.96m0.53%
Wellington Management Co. LLPas of 03 Jul 20258.88m0.53%
Geode Capital Management LLCas of 04 Jul 20257.76m0.46%
More ▼
Data from 31 Dec 2024 - 31 Mar 2025Source: FactSet Research Systems Inc.
Data Provided by LSEG
All markets data located on FT.com is subject to the FT Terms & Conditions
All content on FT.com is for your general information and use only and is not intended to address your particular requirements. In particular, the content does not constitute any form of advice, recommendation, representation, endorsement or arrangement by FT and is not intended to be relied upon by users in making (or refraining from making) any specific investment or other decisions.
Any information that you receive via FT.com is at best delayed intraday data and not "real time". Share price information may be rounded up/down and therefore not entirely accurate. FT is not responsible for any use of content by you outside its scope as stated in the FT Terms & Conditions.